Physician profile
Mark Rigby
NPI 1699413765
$1,575.50
in general payments reported to CMS, 2019-2025
11 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $233 · 2023: $357 · 2024: $436 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.15 | 2022-2025 | Linzess, Skyrizi |
| Intercept Pharmaceuticals, INC. | $238.13 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.94 | 2023 | Zeposia |
| Ardelyx, INC. | $124.66 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $105.36 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $71.73 | 2024-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $64.65 | 2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $20.40 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.01 | 2024 | |
| Novo Nordisk INC | $17.13 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rigby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.